Bio-Rad Laboratories, Inc. Class A Common Stock vs Genuine Parts Company — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.02B), while Genuine Parts Company trades at $122.49 (market cap $17.00B). The key difference: Genuine Parts Company is far larger — about 2.1× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Genuine Parts Company pays a 3.44% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | GPC | |
|---|---|---|
Market Cap | $8.02B | $17.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $339.75 | $149.26 |
52-Week Low | $241.71 | $92.47 |
Enterprise Value | $7.84B | $23.21B |
Dividend Yield | — | 3.44% |
Trailing returns across standard periods
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →